Olema Pharmaceuticals, Inc. to Present Innovative Findings
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), known for its commitment to women's cancer therapies, is set to unveil groundbreaking preclinical combination data. This will be showcased at the prestigious EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The symposium is a widely recognized platform dedicated to discussing advancements in cancer treatment and will take place from October 23-25 in Barcelona.
Presenting Significant Research on Breast Cancer
Olema will feature a series of engaging presentations through posters at this important event. Highlighted research includes the synergistic effects witnessed when combining palazestrant, a complete estrogen receptor antagonist, and everolimus, an mTOR inhibitor, which have shown enhanced tumor suppression in ER+/HER2- breast cancer models. This particular study underscores the potential of targeted therapy approaches in addressing challenging cancer types.
Details of the Key Poster Presentations
During the symposium, Olema will highlight the following poster presentations:
- Title: Combining palazestrant and everolimus
- Poster/Abstract: 211
- Session: Poster Session 300, Exhibition Hall
- Date/Time: October 24, 2024, from 09:00 to 17:30 CEST
- Title: Combining palazestrant and capivasertib
- Poster/Abstract: 212
- Session: Poster Session 300, Exhibition Hall
- Date/Time: October 24, 2024, from 09:00 to 17:30 CEST
- Title: Combining OP-3136 with endocrine therapy
- Poster/Abstract: 230
- Session: Poster Session 300, Exhibition Hall
- Date/Time: October 24, 2024, from 09:00 to 17:30 CEST
Insights into Palazestrant (OP-1250)
Palazestrant (OP-1250) represents a significant advancement in the treatment landscape for women with specific breast cancer types. This oral small molecule is distinct, operating effectively as both a complete estrogen receptor antagonist and a selective estrogen receptor degrader. Clinical trials have showcased its potential to stave off the effects of estrogen-driven transcriptional activity in both standard and resistant forms of ER+ breast cancer.
The ongoing clinical research highlights that palazestrant displays promising anti-tumor efficacy while maintaining a tolerable safety profile. The data suggest that it may effectively engage with other therapeutic options, such as CDK4/6 inhibitors, to enhance overall treatment efficacy.
Olema's Commitment to Women's Health
Olema Oncology dedicates its efforts to redefining treatment standards for women battling cancer. With an innovative pipeline, Olema leverages extensive research into endocrine-driven cancers to develop new therapies. Their ongoing commitment reflects a deeper understanding of the complexities surrounding these cancers as they aim to improve patient outcomes significantly.
Currently, the company prioritizes the clinical development of palazestrant (OP-1250) alongside OP-3136, a potent KAT6 inhibitor, signaling a robust commitment to targeting cancer at multiple pathways.
Learn More About Olema’s Initiatives
The details surrounding the research presentations will follow the symposium's embargo policy, with additional information made available on the Olema's official publications page post-event. The engagement at the symposium aligns perfectly with Olema's vision to innovate in the treatment of cancers that primarily affect women.
Frequently Asked Questions
What is Olema Oncology focused on?
Olema Oncology is dedicated to developing targeted therapies to improve outcomes for women with cancer, particularly breast cancer.
What is the significance of palazestrant?
Palazestrant is an innovative therapy that acts as a complete estrogen receptor antagonist and is under investigation for its effectiveness against ER+/HER2- breast cancer.
Where will the symposium take place?
The EORTC-NCI-AACR Symposium is scheduled to be held in Barcelona, providing a platform for leading-edge cancer research discussion.
How does Olema present its findings?
Olema presents its findings in the form of posters that detail the latest research results, contributing to the scientific community's understanding of cancer therapies.
How can I learn more about Olema's research?
Further information can be accessed via Olema’s official website and their publications page after the symposium.